BioSeek Expands Plan to Screen Compounds for UCB | GenomeWeb
NEW YORK (GenomeWeb News) — BioSeek said today that it has renewed and expanded an agreement to profile and guide optimization of lead compounds for the drug company UCB.
South San Francisco, Calif.-based BioSeek said it will profile selected chemical and biological entities and guide lead optimization of a specific phenotypic hit identified by UCB and characterized using the company’s BioMap screens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.